With the changes in the living patterns and dietary patterns of modern people, the incidence of nutritional and metabolic disorders as well as mental disorders is gradually increasing, and the two interact with each other. It is of great significance to explore the pathologic mechanism of nutritional and metabolic disorders as well as mental disorders and to develop drugs to intervene in the pathogenesis for the understanding and clinical treatment of diseases. With the development and progress of science and technology, high-throughput sequencing such as proteomics, metabolomics, transcriptomics, and microbiomics plays an important role in revealing the pathogenesis of diseases and the mechanism of drug efficacy. In fact, multi-omics technology has now become an important tool for understanding the pathogenesis of diseases and elucidating the efficacy mechanisms of drugs.
This Research Topic aims to deepen our understanding of the role of multi-omics technology in understanding the mechanisms of diseases and exploring pharmacological effects. Focus on the pathogenesis of major diseases and the pharmacodynamic mechanisms of drugs such as nutritional metabolic diseases and mental disorders discovered through proteomics, metabolomics, transcriptomics, microbiome, and other technologies. The overarching goal is to inspire the prevention and treatment of complex diseases and mechanism research.
We welcome Original Research, Meta-analysis, Review, Hypothesis and Theory, Perspective, Brief Research Reports, General Commentary, and Opinion article types.
Sub-topics under the theme include:
• Multi-omics technologies such as proteomics, metabolomics, transcriptomics, and microbiomics reveal the pathogenesis of major diseases such as nutritional metabolism disorders and mental disorders
• Research on the pharmacodynamic mechanism of drugs based on the joint application of proteomics, metabolomics, transcriptomics, and microbiomics
• The latest progress in disease mechanisms and drug efficacy mechanisms revealed based on multi-omics technologies such as proteomics, metabolomics, and transcriptomics
Please note:
If patient data are analyzed, a comprehensive description of the patients including sex, age, diagnostic criteria, inclusion and exclusion criteria, disease stage, therapy received, comorbidities as well as additional clinical information and assessment of clinical response/effects should be included. If genetic, proteomics, metabolomics, or other omics data are analyzed, a comprehensive description of the methods and the rationale for the selection of the specific data studied should be provided. Studies solely based on the analysis of public databases or published evidence, with no further experimental insights or experimental validation, will not be included in this Research Topic.
Studies related to natural compounds, herbal extracts, or traditional medicine products should instead be submitted to the specialty section Ethnopharmacology. All the manuscripts submitted to Ethnopharmacology need to fully comply with the Four Pillars of Best Practice in Ethnopharmacology (you can freely download the full version here) and the ConPhyMP statement: Front. Pharmacol. 13:953205. https://doi.org/10.3389/fphar.2022.953205). You need to check your MS using the ConPhyMP tool, see https://ga-online.org/best-practice// It is essential that the studies focus on specific, pharmacognstically well-defined preparations and these preparations must be characterised chemically if experimental studies are included. Purely in silico analyses of specific preparations using network analysis or docking studies are only considered if a detailed body of novel experimental pharmacological data are included.
With the changes in the living patterns and dietary patterns of modern people, the incidence of nutritional and metabolic disorders as well as mental disorders is gradually increasing, and the two interact with each other. It is of great significance to explore the pathologic mechanism of nutritional and metabolic disorders as well as mental disorders and to develop drugs to intervene in the pathogenesis for the understanding and clinical treatment of diseases. With the development and progress of science and technology, high-throughput sequencing such as proteomics, metabolomics, transcriptomics, and microbiomics plays an important role in revealing the pathogenesis of diseases and the mechanism of drug efficacy. In fact, multi-omics technology has now become an important tool for understanding the pathogenesis of diseases and elucidating the efficacy mechanisms of drugs.
This Research Topic aims to deepen our understanding of the role of multi-omics technology in understanding the mechanisms of diseases and exploring pharmacological effects. Focus on the pathogenesis of major diseases and the pharmacodynamic mechanisms of drugs such as nutritional metabolic diseases and mental disorders discovered through proteomics, metabolomics, transcriptomics, microbiome, and other technologies. The overarching goal is to inspire the prevention and treatment of complex diseases and mechanism research.
We welcome Original Research, Meta-analysis, Review, Hypothesis and Theory, Perspective, Brief Research Reports, General Commentary, and Opinion article types.
Sub-topics under the theme include:
• Multi-omics technologies such as proteomics, metabolomics, transcriptomics, and microbiomics reveal the pathogenesis of major diseases such as nutritional metabolism disorders and mental disorders
• Research on the pharmacodynamic mechanism of drugs based on the joint application of proteomics, metabolomics, transcriptomics, and microbiomics
• The latest progress in disease mechanisms and drug efficacy mechanisms revealed based on multi-omics technologies such as proteomics, metabolomics, and transcriptomics
Please note:
If patient data are analyzed, a comprehensive description of the patients including sex, age, diagnostic criteria, inclusion and exclusion criteria, disease stage, therapy received, comorbidities as well as additional clinical information and assessment of clinical response/effects should be included. If genetic, proteomics, metabolomics, or other omics data are analyzed, a comprehensive description of the methods and the rationale for the selection of the specific data studied should be provided. Studies solely based on the analysis of public databases or published evidence, with no further experimental insights or experimental validation, will not be included in this Research Topic.
Studies related to natural compounds, herbal extracts, or traditional medicine products should instead be submitted to the specialty section Ethnopharmacology. All the manuscripts submitted to Ethnopharmacology need to fully comply with the Four Pillars of Best Practice in Ethnopharmacology (you can freely download the full version here) and the ConPhyMP statement: Front. Pharmacol. 13:953205. https://doi.org/10.3389/fphar.2022.953205). You need to check your MS using the ConPhyMP tool, see https://ga-online.org/best-practice// It is essential that the studies focus on specific, pharmacognstically well-defined preparations and these preparations must be characterised chemically if experimental studies are included. Purely in silico analyses of specific preparations using network analysis or docking studies are only considered if a detailed body of novel experimental pharmacological data are included.
